轩竹生物-B(02575)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02575 轩竹生物-B

交易中 09-14 13:44:54

8.785

-0.155

-1.73%

最高9.250	最低8.560	成交量46.25万
今开8.940	昨收8.940	日振幅7.72%
总市值45.51亿	流通市值45.50亿	总股本5.18亿
成交额405.57万	换手率0.09%	流通股本5.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"轩竹生物-B","latestPrice":8.785,"timestamp":1789364665507,"preClose":8.94,"halted":0,"volume":462500,"delay":0,"changeRate":-0.01733780760626391,"floatShares":517947790,"shares":518000000,"eps":-0.6197362415002,"marketStatus":"交易中","change":-0.155,"latestTime":"09-14 13:44:54","open":8.94,"high":9.25,"low":8.56,"amount":4055682,"amplitude":0.077181,"askPrice":8.785,"askSize":1000,"bidPrice":8.675,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":-0.4924622958283334,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1789373400000},"marketStatusCode":2,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":8.94,"openAndCloseTimeList":[[1789349400000,1789358400000],[1789362000000,1789372800000]],"volumeRatio":0.423801,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02575","defaultTab":"news","newsList":[{"id":"1164847772","title":"轩竹生物-B8月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1164847772","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164847772?lang=zh_cn&edition=full","pubTime":"2026-09-04 19:05","pubTimestamp":1788519951,"startTime":"0","endTime":"0","summary":"2026年9月4日，轩竹生物科技股份有限公司发布截至2026年8月31日的证券变动月报表。报告期内，公司已发行普通股为H股，注册股本人民币517,947,790元，股本未发生任何变动，保持在517,947,790股。公司确认于本月未进行任何新增发行、购回、注销或库藏股相关活动。根据香港联交所上市规则，公司H股已维持符合最低公众持股量要求。公司同时声明，已遵守香港联交所《上市规则》及相关法律法规，现有股本状况整体稳定，后续如有进展将及时披露。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664386607","title":"港股异动 | 四环医药(00460)午前涨近4% 轩竹生物与INNOBIC就吡洛西利于泰国市场达成商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664386607","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664386607?lang=zh_cn&edition=full","pubTime":"2026-09-04 11:52","pubTimestamp":1788493955,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，四环医药午前涨近4%，截至发稿，涨3.92%，报0.795港元，成交额981.3万港元。Innobic(亚洲)将作为经销商，负责目标产品于目标区域的药品注册、本地市场营销及商业化运营。轩竹生物将按约定供货价格供应目标产品，以支持目标产品在目标区域的商业化活动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK4588","00460","02575","BK1600","BK1191","BK1515","BK4585","VXUS","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158047728","title":"轩竹生物-B（02575）与Innobic签署吡洛西利片泰国独家商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1158047728","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158047728?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:21","pubTimestamp":1788427273,"startTime":"0","endTime":"0","summary":"2026年9月3日，轩竹生物科技股份有限公司发布自愿性公告称，其已与Innobic  Co., Ltd及ZaoAn International Trading Co., Ltd签订关于吡洛西利片的三方商业协议，协议有效期至2036年6月30日。根据协议，轩竹生物-B授予Innobic（亚洲）与早安国际在泰国的独家商业化权利，涵盖进口、推广、营销、要约销售、销售及经销等活动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664878545","title":"轩竹生物-B(02575)与INNOBIC就吡洛西利于泰国市场达成商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664878545","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664878545?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:15","pubTimestamp":1788426905,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，集团于近日与泰国制药公司Innobic  Co., Ltd及ZaoAn International Trading Co., Ltd就集团的吡洛西利片签署三方商业协议，协议期限至2036年6月30日届满。根据该协议，集团向Innobic(亚洲)及早安国际共同授予目标产品于泰国区域内的独家商业化权利，该等商业化权利包括在目标区域内进口、推广、营销、要约销售、销售及经销目标产品的权利。Innobic(亚洲)将作为经销商，负责目标产品于目标区域的药品注册、本地市场行销及商业化运营。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491534.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664785438","title":"轩竹生物-B(02575.HK)与INNOBIC就吡洛西利于泰国市场达成商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664785438","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664785438?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:15","pubTimestamp":1788426905,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124650509","title":"轩竹生物-B：授予Innobic（亚洲）与兆安国际在泰国的Birecociclib独家商业化权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1124650509","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124650509?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:14","pubTimestamp":1788426853,"startTime":"0","endTime":"0","summary":"轩竹生物-B宣布，已向Innobic（亚洲）及兆安国际授予其产品Birecociclib在泰国的独家商业化权利。此举标志着该公司在拓展东南亚市场方面迈出了重要一步。Birecociclib作为轩竹生物的核心在研产品之一，其海外授权合作备受业界关注。此次协议的签署，不仅体现了轩竹生物对合作伙伴实力的认可，也展现了其全球化战略的坚定决心。通过携手Innobic（亚洲）与兆安国际这两家深耕亚洲市场的企业，轩竹生物旨在加速该药物在泰国市场的落地与推广。未来，随着合作的深入，Birecociclib有望为泰国患者带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104776053","title":"轩竹生物-B宣布与Innobic达成泰国市场Birecociclib商业合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1104776053","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104776053?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:14","pubTimestamp":1788426851,"startTime":"0","endTime":"0","summary":"轩竹生物-B正式对外披露，已同Innobic就Birecociclib在泰国境内的商业化推广签署合作协议。此举意味着该药物在东南亚市场的布局迈出关键一步。双方将依托各自优势，共同推进产品在泰国的落地与销售。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664382922","title":"轩竹生物-B（02575）午后大涨25% 上半年收入同比大增","url":"https://stock-news.laohu8.com/highlight/detail?id=2664382922","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664382922?lang=zh_cn&edition=full","pubTime":"2026-09-03 13:59","pubTimestamp":1788415158,"startTime":"0","endTime":"0","summary":"金吾财讯 | 轩竹生物-B（02575）午后股价大幅拉升，并曾触发市调机制进入冷静期，截至发稿，报11.78港元，涨25.25%，成交额7051.21万港元。消息面上，公司上半年取得收入6940万元人民币，同比增加288.1%。收入增长主要因新产品上市及纳入国家基本医保药品目录而带动销量增长所致。公司经营开支约为人民币9340万元，同比减少约22.2%。","market":"hk","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990570","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664829917","title":"港股异动 | 轩竹生物-B(02575.HK)午后飙升逾40% 上半年收入同比激增近三倍 今年为轩悦宁完整放量元年","url":"https://stock-news.laohu8.com/highlight/detail?id=2664829917","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664829917?lang=zh_cn&edition=full","pubTime":"2026-09-03 13:37","pubTimestamp":1788413841,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664982596","title":"港股异动 | 轩竹生物-B(02575)午前涨超5% 中期收入同比增加288.1% 对外授权与许可引进双向发力","url":"https://stock-news.laohu8.com/highlight/detail?id=2664982596","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664982596?lang=zh_cn&edition=full","pubTime":"2026-09-03 11:37","pubTimestamp":1788406643,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，轩竹生物-B午前涨超5%，截至发稿，涨5.42%，报9.915港元，成交额277.97万港元。消息面上，轩竹生物-B发布截至2026年6月30日止6个月业绩，该集团期内取得收入6940万元人民币，同比增加288.1%。公告称，收入增长主要因新产品上市及纳入国家基本医保药品目录而带动销量增长所致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1191","BK4588","VXUS","02575","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662938760","title":"轩竹生物-B：上半年亏损7530万元 同比收窄32.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662938760","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662938760?lang=zh_cn&edition=full","pubTime":"2026-08-26 13:51","pubTimestamp":1787723460,"startTime":"0","endTime":"0","summary":"8月26日，轩竹生物-B（02575）发布2026年中期业绩，公司收入约为6940万元，同比增加约288.1%，收入增长主要因新产品上市及纳入国家基本医保药品目录而带动销量增长；公司经营开支约为9340万元，同比减少约22.2%；公司亏损7530万元，同比收窄约32.1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608263854446117.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608263854446117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662764791","title":"轩竹生物-B(02575.HK)发布中期业绩 收入6940万元 同比增加288.1% 四条主线协同推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2662764791","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662764791?lang=zh_cn&edition=full","pubTime":"2026-08-26 12:15","pubTimestamp":1787717734,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138559310","title":"轩竹生物-B（02575）发布2026年中期业绩：营收同比增近3倍 亏损收窄32.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1138559310","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138559310?lang=zh_cn&edition=full","pubTime":"2026-08-26 12:06","pubTimestamp":1787717175,"startTime":"0","endTime":"0","summary":"轩竹生物-B（02575）8月26日披露截至2026年6月30日止六个月未经审计的中期业绩。报告期内，公司收入约人民币69.4百万元，同比大增288.1%；经营开支约人民币93.4百万元，同比减少22.2%，带动期内亏损由上年同期的人民币110.909百万元收窄至人民币75.340百万元，降幅32.1%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662761544","title":"轩竹生物-B盘中涨超8% 公司今日将发中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2662761544","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662761544?lang=zh_cn&edition=full","pubTime":"2026-08-26 10:46","pubTimestamp":1787712360,"startTime":"0","endTime":"0","summary":"模拟交易客户端轩竹生物-B早盘一度涨超8%，截至发稿，股价上涨5.14%，现报11.05港元，成交额363.96万港元。轩竹生物公告，董事会会议将于2026年8月26日（星期三）举行，藉以考虑及批准集团截至2026年6月30日止6个月中期业绩及其刊发，并考虑建议派发中期股息（如有）。值得注意的是，轩竹生物近期公告，新一代PPI抑制剂安奈拉唑钠肠溶片用于成人反流性食管炎的NDA申请已获得NMPA受理，基于与雷贝拉唑随机双盲对照的国内III期试验结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-26/doc-iniprcpy2257981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662912769","title":"港股异动 | 轩竹生物-B(02575.HK)早盘涨超8% 公司今日将发中期业绩 机构指安奈拉唑钠商业化潜力巨大","url":"https://stock-news.laohu8.com/highlight/detail?id=2662912769","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662912769?lang=zh_cn&edition=full","pubTime":"2026-08-26 10:10","pubTimestamp":1787710240,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165181922","title":"轩竹生物-B（02575）定于8月26日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1165181922","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165181922?lang=zh_cn&edition=full","pubTime":"2026-08-13 19:01","pubTimestamp":1786618884,"startTime":"0","endTime":"0","summary":"轩竹生物-B（02575）于2026年8月13日公告，公司董事会将于2026年8月26日（星期三）召开会议，审议并批准集团截至2026年6月30日止六个月的中期业绩及其发布事宜，并同期研究是否建议派发中期股息（如有）。\\n\\n公告披露，截至公告日期，公司董事会成员构成为：执行董事徐艳君女士、史澂空博士；非执行董事李惠英女士、尉丽峰先生及陈燕玲女士；职工董事岳鑫女士；独立非执行董事刘硕先生、王宇女士及范智超先生。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167085498","title":"轩竹生物-B 发布2026年7月股份变动月报，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1167085498","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167085498?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:37","pubTimestamp":1786005444,"startTime":"0","endTime":"0","summary":"轩竹生物科技股份有限公司于2026年8月6日披露截至2026年7月31日的股份变动月报。公告显示，公司注册股本在本月保持不变。根据公告，轩竹生物科技股份有限公司于本月无新增发行、股份回购、注销或库藏股等变动。普通股（H股）截至7月底的已发行股份总数仍为517,947,790股，与上月底的517,947,790股保持一致。公司表示，截至2026年7月末，股本情况总体稳定，注册股本总额为人民币517,947,790元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654071005","title":"【券商聚焦】中邮证券首予轩竹生物（02575）买入评级 指商业化前景获看好","url":"https://stock-news.laohu8.com/highlight/detail?id=2654071005","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654071005?lang=zh_cn&edition=full","pubTime":"2026-07-28 15:40","pubTimestamp":1785224415,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中邮证券发布研报指，轩竹生物-B 新一代PPI抑制剂安奈拉唑钠肠溶片用于成人反流性食管炎的NDA申请已获NMPA受理，该适应症国内患者基数约4000万，临床需求庞大。其首发适应症已纳入医保，目前覆盖近3000家医疗终端，较前代PPI抑制剂具备临床优势，较P-CAB类具备价格和安全性优势，商业化前景获看好。基于公司商业化产品逐渐放量、在研管线丰富，首次覆盖，给予“买入”评级。风险提示包括产品销售、新药临床进度及数据不及预期。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986912","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","161027","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653240080","title":"轩竹生物(02575)续跌6% 涉与合作企业技术转让纠纷 仲裁赔付933万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653240080","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653240080?lang=zh_cn&edition=full","pubTime":"2026-07-21 10:39","pubTimestamp":1784601589,"startTime":"0","endTime":"0","summary":"金吾财讯 | 轩竹生物(02575)低位震荡，报11.14元，跌5.99%，成交额177.6万元。消息面上，轩竹生物披露仲裁结果，公司与合作生物技术企业因 2021 年药品技术转让合同产生纠纷，对方曾将特定药品国内上市、商业化独家权益转让给轩竹生物，后续该品类仿制药纳入国家集采，同类药品价格大幅下行，叠加研发成果、GMP 核查进度分歧，双方协商合同免责终止无果。合作方 2024 年向中国国际经济贸易仲裁委员会提交仲裁申请，诉求确认合同终止并索要经济赔偿。仲裁庭于 7 月 15 日出具终局裁决，裁定轩竹生物合计支付约 933 万元人民币，该裁决具备终局法律约束力。","market":"sh","thumbnail":"https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986365","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652726461","title":"板块热度升温、估值逻辑重塑，轩竹生物-B（2575.HK）商业化放量箭在弦上","url":"https://stock-news.laohu8.com/highlight/detail?id=2652726461","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652726461?lang=zh_cn&edition=full","pubTime":"2026-07-20 12:19","pubTimestamp":1784521195,"startTime":"0","endTime":"0","summary":"轩竹生物当前业务层面的关键变量正在加速落地，恰处于这一价值重估的节点上。","market":"us","thumbnail":"https://img7.gelonghui.com/column/7.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/7.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5642242","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xuanzhubio.com","stockEarnings":[{"period":"1week","weight":-0.1429},{"period":"1month","weight":-0.3097},{"period":"3month","weight":-0.4492},{"period":"6month","weight":-0.8212},{"period":"1year","weight":-0.2293},{"period":"ytd","weight":-0.8732}],"compareEarnings":[{"period":"1week","weight":-0.033},{"period":"1month","weight":-0.0249},{"period":"3month","weight":0.0035},{"period":"6month","weight":-0.0259},{"period":"1year","weight":-0.0491},{"period":"ytd","weight":-0.0322}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。该公司主要从事研发、生产及商业化创新药的业务，专注于消化、肿瘤和非酒精性脂肪性肝炎（NASH）等多个治疗领域。该公司主要产品包括KBP-3571、XZP-3287及XZP-3621。该公司主要在中国国内开展业务。","exchange":"SEHK","name":"轩竹生物-B","nameEN":"XUANZHUBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"轩竹生物-B(02575)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供轩竹生物-B(02575)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"轩竹生物-B,02575,轩竹生物-B股票,轩竹生物-B股票老虎,轩竹生物-B股票老虎国际,轩竹生物-B行情,轩竹生物-B股票行情,轩竹生物-B股价,轩竹生物-B股市,轩竹生物-B股票价格,轩竹生物-B股票交易,轩竹生物-B股票购买,轩竹生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"轩竹生物-B(02575)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供轩竹生物-B(02575)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}